A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding

PharmacoEconomics

Volumn 32, Issue 8, 2014, Pages 801-813

  Sruamsiri, Rosarin ^a   Dilokthornsakul, Piyameth ^a   Pratoomsoot, Chayanin ^a   Chaiyakunapruk, Nathorn ^a,b,c,d  

^a NARESUAN UNIVERSITY   (Thailand)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

ARTICLE; BLEEDING; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DECISION TREE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STOCHASTIC MODEL; SYSTEMATIC REVIEW; THAILAND; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; CHILD; COMPLICATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE COST; HEMORRHAGE; HOSPITALIZATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

CHILD; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; HEALTH CARE COSTS; HEMORRHAGE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MARKOV CHAINS; MODELS, ECONOMIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; THAILAND;

EID: 84906935703     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0171-9     Document Type: Article

References (60)

1. Millan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;304(19):1135-47. (Pubitemid 11099209)
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
3. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350(9078):620-3. (Pubitemid 27367795)
4. Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, et al. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol. 2000;17(7):551-8.
5. Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer. 2008;51(4):513-6.
6. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
7. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin N Am. 2010;24(1):249-73.
8. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40. (Pubitemid 26230668)
9. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost. 2003;29:605-17. (Pubitemid 38041412)
10. Neunert CE, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-207.
11. Provan D, Nokes T, Agrawal S, Winer J, Wood P. Clinical guidelines for immunoglobulin use. Department of Health, NHS, UK; 2008.
12. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(Suppl 1):S9-56.
13. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-96.
14. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40. (Pubitemid 26230668)
15. Condino-Neto A, Franco JL, Trujillo-Vargas C, Espinosa-Rosales FJ, Leiva LE, Rodriguez-Quiroz F, et al. Critical issues and needs in management of primary immunodeficiency diseases in Latin America. Allergol Immunopathol (Madr). 2011;39(1):45-51.
16. National Drug Committee. National list of essential medicine 2012. 2013. http://www.nlem.in.th/sites/default/files/essential-book.pdf. Accessed 26 Aug 2013.
17. Roseman CB, Patrick WK, Tucker RV. Health technology assessment: a policy-relevant technology diffusion model for emerging economies of the Asia and Pacific region. Asia Pac J Public Health. 1991;5(1):10-4.
18. Sivalal S. Health technology assessment in the Asia Pacific region. Int J Technol Assess Health Care. 2009;25(Suppl 1):196-201.
19. Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Assessment Guideline. J Med Assoc Thai 2008;91(Suppl 2):S1-S88.
20. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77(1):31-3.
21. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133(3):334-9. (Pubitemid 28413613)
22. Beck C, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147:521-7. (Pubitemid 41446548)
23. DerSimonian RLN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
24. Hemmila MR, Foley DS, Castle VP, Hirschl RB. The response to splenectomy in pediatric patients with idiopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin. J Pediatr Surg. 2000;35(6):967-71.
25. Fabris F, Cordiano I, Girolami A. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;337:1088-9.
26. Schneider P, Wehmeier A, Schneider W. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;337:1087-8.
27. Kwon HC, Moon CH, Cho YR, Kim MC, Kim KH, Han JY, et al. Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura. J Korean Med Sci. 2005;20(3):417-20.
28. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;336(21):1494-8. (Pubitemid 27215164)
29. Hollander LL, Leys CM, Weil BR, Rescorla FJ. Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura. Surgery. 2011;150(4):643-8.
30. Mantadakis E, Buchanan GR. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2000;22(2):148-53. (Pubitemid 32290151)
31. Aronis S, Platokouki H, Mitsika A, Haidas S, Constantopoulos A. Seventeen years of experience with chronic idiopathic thrombocytopenic purpura in childhood. Is therapy always better? Pediatr Hematol Oncol. 1994;11(5):487-98. (Pubitemid 24280831)
32. Koçak U, Aral YZ, Kaya Z, Oztürk G, Gürsel T. Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura: a single center's experience. Turk J Pediatr. 2007;49(3):250-5. (Pubitemid 47554893)
33. Belletrutti M, Ali K, Barnard D, Blanchette V, Chan A, David M, et al. Chronic immune thrombocytopenic purpura in children: a survey of the Canadian experience. J Pediatr Hematol Oncol. 2007;29(2):95-100. (Pubitemid 46213855)
34. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122-5. (Pubitemid 34094903)
35. Glanz J, France E, Xu S, Hayes T, Hambidge S. A populationbased, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pedatrics. 2008;121(3):e506-12.
36. Health Information Group. Bureau of Health Policy and Strategy MoPHT. Public Health Statistics A.D.2009. http://203.157.19.191/input-bps.htm.
37. Aronis S, Platokouki H, Avgeri M, Pergantou H, Keramidas D. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr. 2004;93:638-42. (Pubitemid 38570231)
38. Donato H, Picon A, Rapetti MC. Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2006;47:373-9.
39. Wang T, Xu M, Ji L. Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematol. 2006;115:39-45. (Pubitemid 43130431)
40. Yong M, Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, et al. Mortality risk in splenectomised patients: a Danish population-based cohort study. Eur J Intern Med. 2010;21(1):12-6.
41. Riewpaiboon A. Standard cost lists for health technology assessment. Bangkok: Faculty of Pharmacy, Mahidol University; 2010.
42. Bank of Thailand. Exchange rate. 2013. http://www2.bot.or.th/statistics/ BOTWEBSTAT.aspx?reportID=145&language=TH. Accessed 30 Dec 2013.
43. Bank of Thailand. EC-EI-027: Thailand's macro economic indicators 1. 2012. http://www2.bot.or.th/statistics/ReportPage.aspx?reportID= 409&language=eng. Accessed 8 July 2013.
44. Ministry of Public Health Thailand. Drug Medical Supply and Information Center (DMSIC). http://dmsic.moph.go.th/price.htm. Accessed 26 Dec 2012.
45. Drummond MF, Mark JS, George WT. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
46. Ministry of Public Health Network of Unit Cost. Unit cost manual for hospital: MUCC; 2011.
47. Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14(8):1142-5.
48. Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24(10):2767-76.
49. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203-20. (Pubitemid 40353904)
50. Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Assessment Guideline. J Med Assoc Thai. 2008;91(Suppl.2):S1-S88.
51. Meeyai A, Kotirum S, Praditsitthikorn N, Kulpeng W, Cooper B, Teerawattananon Y. Cost-utility analysis of seasonal influenza vaccine among school children in Thailand. Bangkok: Health Intervention and Technology Assessment Program (HITAP); 2013.
52. Meeting of Subcommittee for Development of the National List of Essential Drugs. Nonthaburi: Food and Drug Administration; 2012. p. 7.
53. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
54. Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thail. 2008;91(Suppl 2):S59-65.
55. Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, et al. Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. J Popul Ther Clin Pharmacol. 2012;19(2):e166-78.
56. O'Brien SH, Ritchey AK, Smith KJ. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer. 2007;48(2):173-80. (Pubitemid 44958274)
57. Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605-8. (Pubitemid 37452786)
58. Donato H, Picón A, Martinez M, Rapetti MC, Rosso A, Gomez S, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer. 2009;52(4):491-6.
59. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133(3):334-9. (Pubitemid 28413613)
60. Blanchette V, Imbach P, AndrewM, AdamsM, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344(8924):703-7. (Pubitemid 24281420)